Roberto Salvatori

List of Publications by Year
in descending order

200	6,604	87888 38	85541 71
papers	citations	h-index	g-index

202	202	202	4591
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3888-3921.	3.6	601
2	Endocrine Side Effects Induced by Immune Checkpoint Inhibitors. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 1361-1375.	3.6	358
3	Clinical Characteristics and Therapeutic Responses in Patients with Germ-LineAIPMutations and Pituitary Adenomas: An International Collaborative Study. Journal of Clinical Endocrinology and Metabolism, 2010, 95, E373-E383.	3.6	323
4	Consensus on diagnosis and management of Cushing's disease: a guideline update. Lancet Diabetes and Endocrinology,the, 2021, 9, 847-875.	11.4	315
5	A Consensus on the Diagnosis and Treatment of Acromegaly Comorbidities: An Update. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e937-e946.	3.6	207
6	Familial Dwarfism due to a Novel Mutation of the Growth Hormone-Releasing Hormone Receptor Gene¹. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 917-923.	3.6	188
7	Multidisciplinary management of acromegaly: A consensus. Reviews in Endocrine and Metabolic Disorders, 2020, 21, 667-678.	5.7	183
8	Familial Dwarfism due to a Novel Mutation of the Growth Hormone-Releasing Hormone Receptor Gene. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 917-923.	3.6	173
9	A Mouse with Targeted Ablation of the Growth Hormone-Releasing Hormone Gene: A New Model of Isolated Growth Hormone Deficiency. Endocrinology, 2004, 145, 4134-4143.	2.8	117
10	Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 17-26.	11.4	116
11	Recurrence of Hyperprolactinemia after Withdrawal of Long-Term Cabergoline Therapy. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2428-2436.	3.6	104
12	ENDOCRINE SIDE-EFFECTS OF ANTI-CANCER DRUGS: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. European Journal of Endocrinology, 2013, 169, R153-R164.	3.7	102
13	Familial Isolated Growth Hormone Deficiency Is Associated with Increased Systolic Blood Pressure, Central Obesity, and Dyslipidemia. Journal of Clinical Endocrinology and Metabolism, 2002, 87, 2018-2023.	3.6	94
14	Three New Mutations in the Gene for the Growth Hormone (GH)-Releasing Hormone Receptor in Familial Isolated GH Deficiency Type IB1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 273-279.	3.6	92
15	Longevity in Untreated Congenital Growth Hormone Deficiency Due to a Homozygous Mutation in the GHRH Receptor Gene. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 714-721.	3.6	92
16	Current best practice in the management of patients after pituitary surgery. Therapeutic Advances in Endocrinology and Metabolism, 2017, 8, 33-48.	3.2	88
17	Effect of Severe Growth Hormone (GH) Deficiency due to a Mutation in the GH-Releasing Hormone Receptor on Insulin-Like Growth Factors (IGFs), IGF-Binding Proteins, and Ternary Complex Formation Throughout Life1. Journal of Clinical Endocrinology and Metabolism, 1999, 84, 4118-4126.	3.6	81
18	Three New Mutations in the Gene for the Growth Hormone (GH)-Releasing Hormone Receptor in Familial Isolated GH Deficiency Type IB. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 273-279.	3.6	78

#	Article	IF	Citations
19	Lack of Evidence of Premature Atherosclerosis in Untreated Severe Isolated Growth Hormone (GH) Deficiency due to a GH-Releasing Hormone Receptor Mutation. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 2093-2099.	3.6	76
20	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site. Molecular Endocrinology, 2002, 16, 450-458.	3.7	73
21	Cushing Syndrome: Maybe Not So Uncommon of an Endocrine Disease. Journal of the American Board of Family Medicine, 2012, 25, 199-208.	1.5	72
22	Effect of dopaminergic drug treatment on surgical findings in prolactinomas. Pituitary, 2011, 14, 68-74.	2.9	67
23	Adrenal Insufficiency. JAMA - Journal of the American Medical Association, 2005, 294, 2481.	7.4	66
24	Detection of Pituitary Antibodies by Immunofluorescence: Approach and Results in Patients With Pituitary Diseases. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1758-1766.	3.6	66
25	Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naÃ¯ve patients with acromegaly. Pituitary, 2010, 13, 115-122.	2.9	61
26	Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial. Lancet Diabetes and Endocrinology,the, 2019, 7, 855-865.	11.4	60
27	Congenital Growth Hormone (GH) Deficiency and Atherosclerosis: Effects of GH Replacement in GH-Naive Adults. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4664-4670.	3.6	57
28	A new missense mutation in the growth hormone-releasing hormone receptor gene in familial isolated GH deficiency. European Journal of Endocrinology, 2003, 148, 25-30.	3.7	55
29	MECHANISMS IN ENDOCRINOLOGY: The multiple facets of GHRH/GH/IGF-I axis: lessons from lifetime, untreated, isolated GH deficiency due to a GHRH receptor gene mutation. European Journal of Endocrinology, 2017, 177, R85-R97.	3.7	51
30	Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 3279-3283.	3.6	50
31	Isolated growth hormone (GH) deficiency due to compound heterozygosity for two new mutations in the GHâ€releasing hormone receptor gene. Clinical Endocrinology, 2001, 54, 681-687.	2.4	46
32	Magnetic resonance imaging study of pituitary morphology in subjects homozygous and heterozygous for a null mutation of the GHRH receptor gene. European Journal of Endocrinology, 2003, 148, 427-432.	3.7	46
33	Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry. Pituitary, 2014, 17, 13-21.	2.9	44
34	Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance. Pituitary, 2017, 20, 109-115.	2.9	44
35	Variability in anterior pituitary size within members of a family with GH deficiency due to a new splice mutation in the GHRH receptor gene. Clinical Endocrinology, 2004, 60, 470-475.	2.4	43
36	Clinical features of sellar and suprasellar meningiomas. Pituitary, 2014, 17, 342-348.	2.9	43

#	Article	IF	Citations
37	Insulin Sensitivity and Î²-Cell Function in Adults with Lifetime, Untreated Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1013-1019.	3.6	42
38	Sizes of abdominal organs in adults with severe short stature due to severe, untreated, congenital GH deficiency caused by a homozygous mutation in the GHRH receptor gene. Clinical Endocrinology, 2008, 69, 153-158.	2.4	41
39	EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e917-e925.	3.6	37
40	Endoscopic Versus Microscopic Transsphenoidal Approach for Pituitary Adenomas: Comparison of Outcomes During the Transition of Methods of a Single Surgeon. World Neurosurgery, 2017, 97, 317-325.	1.3	36
41	The 5-factor modified frailty index predicts health burden following surgery for pituitary adenomas. Pituitary, 2020, 23, 630-640.	2.9	36
42	Serum GH response to pharmacological stimuli and physical exercise in two siblings with two new inactivating mutations in the GH-releasing hormone receptor gene. European Journal of Endocrinology, 2002, 147, 591-596.	3.7	34
43	Effects of recombinant mouse growth hormone treatment on growth and body composition in GHRH knock out mice. Growth Hormone and IGF Research, 2005, 15, 275-282.	1.1	34
44	Adipokine Profile and Urinary Albumin Excretion in Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 693-698.	3.6	34
45	More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. European Journal of Endocrinology, 2021, 185, 525-538.	3.7	32
46	Detection of a recurring mutation in the human growth hormone-releasing hormone receptor gene. Clinical Endocrinology, 2002, 57, 77-80.	2.4	31
47	Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?. Journal of the Endocrine Society, 2021, 5, bvaa205.	0.2	31
48	Advances in differential diagnosis and management of growth hormone deficiency in children. Nature Reviews Endocrinology, 2021, 17, 608-624.	9.6	31
49	Heterozygosity for a Mutation in the Growth Hormone-Releasing Hormone Receptor Gene Does Not Influence Adult Stature, But Affects Body Composition. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 2353-2357.	3.6	29
50	Surgical treatment of microprolactinomas: pros. Endocrine, 2014, 47, 725-729.	2.3	29
51	Thyroid Morphology and Function in Adults with Untreated Isolated Growth Hormone Deficiency. Journal of Clinical Endocrinology and Metabolism, 2006, 91, 860-864.	3.6	28
52	Increased Visceral Adiposity and Cortisol to Cortisone Ratio in Adults With Congenital Lifetime Isolated GH Deficiency. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 3285-3289.	3.6	28
53	Second attempt to withdraw cabergoline in prolactinomas: a pilot study. Pituitary, 2014, 17, 451-456.	2.9	28
54	Consequences of lifetime isolated growth hormone (GH) deficiency and effects of shortâ€term GH treatment on bone in adults with a mutation in the GHRHâ€receptor gene. Clinical Endocrinology, 2009, 70, 35-40.	2.4	27

#	Article	IF	Citations
55	<scp>ACTH</scp>â€secreting pituitary microadenomas are associated with a higher prevalence of central hypothyroidism compared to other microadenoma types. Clinical Endocrinology, 2012, 77, 871-876.	2.4	27
56	Absence of mutations in the growth hormone (GH)-releasing hormone receptor gene in GH-secreting pituitary adenomas. Clinical Endocrinology, 2001, 54, 301-307.	2.4	26
57	Study of the Multiple Endocrine Neoplasia Type 1, Growth Hormone-Releasing Hormone Receptor, Gsî±, and Gi2î± Genes in Isolated Familial Acromegaly1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 542-544.	3.6	26
58	Partial Rescue of Growth Failure in Growth Hormone (GH)-Deficient Mice by a Single Injection of a Double-Stranded Adeno-Associated Viral Vector Expressing the GH Gene Driven by a Muscle-Specific Regulatory Cassette. Human Gene Therapy, 2009, 20, 759-766.	2.7	26
59	Ectopic Cushing's syndrome: some facts. Indian Journal of Medical Research, 2009, 129, 4-6.	1.0	26
60	Growth Hormone and IGF-1. Reviews in Endocrine and Metabolic Disorders, 2004, 5, 15-23.	5.7	25
61	Cephalometric features in isolated growth hormone deficiency. Angle Orthodontist, 2011, 81, 578-583.	2.4	25
62	Increased locomotor and thermogenic activity in mice with targeted ablation of the GHRH gene. Growth Hormone and IGF Research, 2015, 25, 80-84.	1.1	25
63	Therapeutic augmentation of the growth hormone axis to improve outcomes following peripheral nerve injury. Expert Opinion on Therapeutic Targets, 2016, 20, 1259-1265.	3.4	25
64	Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically Ill Surgical Patients. Antimicrobial Agents and Chemotherapy, 2004, 48, 2471-2476.	3.2	24
65	Familial Growth Hormone Deficiency and Mutations in the GHRH Receptor Gene. Vitamins and Hormones, 2004, 69, 209-220.	1.7	24
66	Partial Reversibility of Growth Hormone (GH) Deficiency in the GH-Releasing Hormone (GHRH) Knockout Mouse by Postnatal Treatment with a GHRH Analog. Endocrinology, 2005, 146, 1506-1513.	2.8	24
67	Chapter 3 Diseases Associated with Growth Hormoneâ€Releasing Hormone Receptor (GHRHR) Mutations. Progress in Molecular Biology and Translational Science, 2009, 88, 57-84.	1.7	24
68	Infectious diseases and immunological responses in adult subjects with lifetime untreated, congenital GH deficiency. Endocrine, 2016, 54, 182-190.	2.3	24
69	Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e1953-e1967.	3.6	24
70	GH, But Not GHRH, Plays a Role in the Development of Experimental Autoimmune Encephalomyelitis. Endocrinology, 2011, 152, 3803-3810.	2.8	23
71	Behavioural phenotyping of male growth hormone-releasing hormone (GHRH) knockout mice. Growth Hormone and IGF Research, 2014, 24, 192-197.	1.1	23
72	Disruption of the GHRH receptor and its impact on children and adults: The Itabaianinha syndrome. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 81-89.	5.7	23

#	Article	IF	Citations
73	Familial growth hormone deficiency with mutated GHRH receptor gene: clinical and hormonal findings in homozygous and heterozygous individuals from Itabaianinha. European Journal of Endocrinology, 2000, 142, 557-563.	3.7	22
74	Naturally-occurring missense mutations in the human growth hormone-releasing hormone receptor alter ligand binding. Journal of Endocrinology, 2005, 186, 515-521.	2.6	22
75	Quality of life in congenital, untreated, lifetime isolated growth hormone deficiency. Psychoneuroendocrinology, 2009, 34, 894-900.	2.7	22
76	Laryngeal and vocal evaluation in untreated growth hormone deficient adults. Otolaryngology - Head and Neck Surgery, 2009, 140, 37-42.	1.9	22
77	ACTH-secreting pituitary adenomas: size does not correlate with hormonal activity. Pituitary, 2012, 15, 526-532.	2.9	22
78	Growth Hormone Should Be Used Only for Approved Indications. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 409-411.	3.6	22
79	The Somatotrope Growth Hormone-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor-1 Axis in Immunoregulation and Immunosenescence. Frontiers of Hormone Research, 2017, 48, 147-159.	1.0	22
80	Decreased Expression of the GHRH Receptor Gene Due to a Mutation in a Pit-1 Binding Site. Molecular Endocrinology, 2002, 16, 450-458.	3.7	22
81	A new mutation in the growth hormone-releasing hormone receptor gene in two Israeli Arab families. Journal of Endocrinological Investigation, 2006, 29, 122-130.	3.3	21
82	A Novel Frame Shift Mutation in the GHRH Receptor Gene in Familial Isolated GH Deficiency: Early Occurrence of Anterior Pituitary Hypoplasia. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2982-2986.	3.6	21
83	Isolated GH Deficiency due to a GHRH Receptor Mutation Causes Hip Joint Problems and Genu Valgum, and Reduces Size but not Density of Trabecular and Mixed Bone. Journal of Clinical Endocrinology and Metabolism, 2013, 98, E1710-E1715.	3.6	21
84	The Severe Deficiency of the Somatotrope GH-Releasing Hormone/Growth Hormone/Insulin-Like Growth Factor 1 Axis of Ghrhâˆ’/âˆ’ Mice Is Associated With an Important Splenic Atrophy and Relative B Lymphopenia. Frontiers in Endocrinology, 2018, 9, 296.	3.5	21
85	Thyrotoxicosis due to metastatic papillary thyroid cancer in a patient with Gravesâ€™ disease. Journal of Endocrinological Investigation, 2002, 25, 639-642.	3.3	20
86	Voice Quality in Short Stature With and Without GH Deficiency. Journal of Voice, 2012, 26, 673.e13-673.e19.	1.5	20
87	Hearing Status in Adult Individuals with Lifetime, Untreated Isolated Growth Hormone Deficiency. Otolaryngology - Head and Neck Surgery, 2014, 150, 464-471.	1.9	20
88	Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushingâ€™s syndrome. Pituitary, 2021, 24, 104-115.	2.9	20
89	Metastatic renal cell carcinoma to the pituitary presenting with hyperprolactinemia. Journal of Endocrinological Investigation, 2004, 27, 471-474.	3.3	19
90	Familial Isolated Pituitary Adenomas: From Genetics to Therapy. Clinical and Translational Science, 2011, 4, 55-62.	3.1	19

#	Article	IF	Citations
91	Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor. Pituitary, 2012, 15, 61-67.	2.9	19
92	Molecular and Clinical Aspects of GHRH Receptor Mutations. Endocrine Development, 2013, 24, 106-117.	1.3	19
93	Brazilian adult individuals with untreated isolated GH deficiency do not have accelerated subclinical atherosclerosis. Endocrine Connections, 2016, 5, 41-46.	1.9	19
94	Effects of long-term treatment with growth hormone-releasing peptide-2 in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 2005, 289, E762-E767.	3.5	18
95	Metabolic effects of growth hormone (GH) replacement in children and adolescents with severe isolated GH deficiency due to a GHRH receptor mutation. Clinical Endocrinology, 2007, 66, 070115055241013.	2.4	18
96	Climacteric in untreated isolated growth hormone deficiency. Menopause, 2008, 15, 743-747.	2.0	18
97	Voice Formants in Individuals With Congenital, Isolated, Lifetime Growth Hormone Deficiency. Journal of Voice, 2016, 30, 281-286.	1.5	18
98	Novel Somatostatin Receptor Ligands Therapies for Acromegaly. Frontiers in Endocrinology, 2018, 9, 78.	3.5	18
99	Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study. European Journal of Endocrinology, 2020, 183, 453-462.	3.7	18
100	Effects of isolated GH deficiency on adipose tissue, feeding and adipokines in mice. Growth Hormone and IGF Research, 2013, 23, 237-242.	1.1	17
101	Behavioural phenotyping, learning and memory in young and aged growth hormone-releasing hormone-knockout mice. Endocrine Connections, 2018, 7, 924-931.	1.9	17
102	Adult individuals with congenital, untreated, severe isolated growth hormone deficiency have satisfactory muscular function. Endocrine, 2019, 63, 112-119.	2.3	17
103	Lifetime congenital isolated GH deficiency does not protect from the development of diabetes. Endocrine Connections, 2013, 2, 112-117.	1.9	16
104	Long-acting pasireotide improves clinical signs and quality of life in Cushingâ€™s disease: results from a phase III study. Journal of Endocrinological Investigation, 2020, 43, 1613-1622.	3.3	16
105	GH response to hypoglycemia and clonidine in the GH-releasing hormone resistance syndrome. Journal of Endocrinological Investigation, 2006, 29, 805-808.	3.3	15
106	Treatment of hypopituitarism in patients receiving antiepileptic drugs. Lancet Diabetes and Endocrinology,the, 2015, 3, 132-140.	11.4	15
107	Effects of Combined Long-Term Treatment with a Growth Hormone-Releasing Hormone Analogue and a Growth Hormone Secretagogue in the Growth Hormone-Releasing Hormone Knock Out Mouse. Neuroendocrinology, 2005, 82, 198-207.	2.5	14
108	Subjects with isolated GH deficiency due to a null GHRHR mutation eat proportionally more, but healthier than controls. Endocrine, 2016, 51, 317-322.	2.3	14

#	Article	IF	Citations
109	Predictors of the Response to Dopaminergic Therapy in Patients With Prolactinoma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4558-e4566.	3.6	14
110	Effects of GH deficiency and GH replacement on inter-male aggressiveness in mice. Growth Hormone and IGF Research, 2011, 21, 76-80.	1.1	13
111	Perioperative Corticosteroid Management for Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2015, 21, 221-228.	1.9	13
112	CT Appearance of Adrenal Cystic Lymphangioma: Radiologic-Pathologic Correlation. American Journal of Roentgenology, 2016, 206, 81-85.	2.2	13
113	Growth Hormone (GH) Deficient Mice With GHRH Gene Ablation Are Severely Deficient in Vaccine and Immune Responses Against Streptococcus pneumoniae. Frontiers in Immunology, 2018, 9, 2175.	4.8	13
114	Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology - Endocrinology and Metabolism, 2006, 291, E1290-E1294.	3.5	12
115	Lifetime, untreated isolated GH deficiency due to a GH-releasing hormone receptor mutation has beneficial consequences on bone status in older individuals, and does not influence their abdominal aorta calcification. Endocrine, 2014, 47, 191-7.	2.3	12
116	Discovery of Cushingâ€™s Syndrome After Bariatric Surgery: Multicenter Series of 16 Patients. Obesity Surgery, 2015, 25, 2306-2313.	2.1	12
117	Abnormal vascular and neural retinal morphology in congenital lifetime isolated growth hormone deficiency. Growth Hormone and IGF Research, 2016, 30-31, 11-15.	1.1	12
118	Effects of growth hormone-releasing hormone gene targeted ablation on ghrelin-induced feeding. Growth Hormone and IGF Research, 2017, 37, 40-46.	1.1	12
119	In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism. European Journal of Endocrinology, 2017, 177, 257-266.	3.7	12
120	Comparative Cost Analysis of Endoscopic versus Microscopic Endonasal Transsphenoidal Surgery for Pituitary Adenomas. Journal of Neurological Surgery, Part B: Skull Base, 2018, 79, 131-138.	0.8	12
121	Vitamin A deficiency does not influence longitudinal growth in mice. Nutrition, 2007, 23, 483-488.	2.4	11
122	Prevalence of antipituitary antibodies in acromegaly. Pituitary, 2012, 15, 490-494.	2.9	11
123	Growth hormone deficiency in patients with obesity. Endocrine, 2015, 49, 304-306.	2.3	11
124	Temozolomide retreatment in a recurrent prolactin-secreting pituitary adenoma: Hormonal and radiographic response. Journal of Oncology Pharmacy Practice, 2016, 22, 517-522.	0.9	11
125	Altered sleep patterns in patients with non-functional GHRH receptor. European Journal of Endocrinology, 2017, 177, 51-57.	3.7	11
126	Occurrence of neoplasms in individuals with congenital, severe GH deficiency from the Itabaianinha kindred. Growth Hormone and IGF Research, 2018, 41, 71-74.	1.1	11

#	Article	IF	Citations
127	Management Options for Persistent Postoperative Acromegaly. Neurosurgery Clinics of North America, 2012, 23, 621-638.	1.7	10
128	Increased pain and inflammatory sensitivity in growth hormone-releasing hormone (GHRH) knockout mice. Prostaglandins and Other Lipid Mediators, 2019, 144, 106362.	1.9	10
129	Macrophages From Subjects With Isolated GH/IGF-I Deficiency Due to a GHRH Receptor Gene Mutation Are Less Prone to Infection by Leishmania amazonensis. Frontiers in Cellular and Infection Microbiology, 2019, 9, 311.	3.9	10
130	A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. Pituitary, 2017, 20, 605-618.	2.9	10
131	Prolactin and sex steroids levels in congenital lifetime isolated GH deficiency. Endocrine, 2013, 44, 207-211.	2.3	9
132	Liver status in congenital, untreated, isolated GH deficiency. Endocrine Connections, 2014, 3, 132-137.	1.9	9
133	Venous Sampling for Cushing Disease: Comparison of Internal Jugular Vein and Inferior Petrosal Sinus Sampling. Endocrine Practice, 2016, 22, 1057-1061.	2.1	9
134	Ocular findings in adult subjects with an inactivating mutation in GH releasing hormone receptor gene. Growth Hormone and IGF Research, 2017, 34, 8-12.	1.1	9
135	Effects of Therapy With Semi-occluded Vocal Tract and Choir Training on Voice in Adult Individuals With Congenital, Isolated, Untreated Growth Hormone Deficiency. Journal of Voice, 2019, 33, 808.e1-808.e5.	1.5	9
136	Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. Pharmacological Research, 2020, 152, 104614.	7.1	9
137	Circulating microRNA profile in humans and mice with congenital GH deficiency. Aging Cell, 2021, 20, e13420.	6.7	9
138	Immune Checkpoint Inhibitor-Induced Central Diabetes Insipidus: Looking for the Needle in the Haystack or a Very Rare Side-Effect to Promptly Diagnose?. Frontiers in Oncology, 2022, 12, 798517.	2.8	9
139	Cushingâ€™s Syndrome Attributable to Ectopic Secretion of Corticotropin in A Patient with Two Neuroendocrine Tumors. Endocrine Practice, 2006, 12, 656-659.	2.1	8
140	Usefulness of an ad hoc questionnaire (Acro-CQ) for the systematic assessment of acromegaly comorbidities at diagnosis and their management at follow-up. Journal of Endocrinological Investigation, 2016, 39, 1277-1284.	3.3	8
141	Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to a GHRH Receptor Gene Mutation. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2777-2784.	3.6	8
142	Hypophysitis in the era of immune checkpoint inhibitors and immunoglobulin G4-related disease. Expert Review of Endocrinology and Metabolism, 2019, 14, 167-178.	2.4	8
143	Preoperative BMI Predicts Postoperative Weight Gain in Adult-onset Craniopharyngioma. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 1603-1617.	3.6	8
144	Levoketoconazole: a novel treatment for endogenous Cushing's syndrome. Expert Review of Endocrinology and Metabolism, 2021, 16, 159-174.	2.4	8

#	Article	IF	Citations
145	Influence of Estrogen Administration on the Growth Response to Growth Hormone (GH) in GH-Deficient Mice. Experimental Biology and Medicine, 2005, 230, 715-720.	2.4	7
146	Autosomal-Dominant Isolated Growth Hormone Deficiency (IGHD Type II) with Normal GH-1 Gene. Hormone Research in Paediatrics, 2006, 65, 76-82.	1.8	7
147	Mutation Analysis of the Muscarinic Cholinergic Receptor Genes in Isolated Growth Hormone Deficiency Type IB. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 2565-2570.	3.6	7
148	Arrest of atherosclerosis progression after interruption of GH replacement in adults with congenital isolated GH deficiency. European Journal of Endocrinology, 2012, 166, 977-982.	3.7	7
149	Walter E. Dandy: his contributions to pituitary surgery in the context of the overall Johns Hopkins Hospital experience. Pituitary, 2017, 20, 683-691.	2.9	7
150	Sweat and vitamin D status in congenital, lifetime, untreated GH deficiency. Endocrine, 2019, 65, 710-713.	2.3	7
151	Formant Frequencies, Cephalometric Measures, and Pharyngeal Airway Width in Adults With Congenital, Isolated, and Untreated Growth Hormone Deficiency. Journal of Voice, 2021, 35, 61-68.	1.5	7
152	Patient-reported outcomes in patients with acromegaly treated with pegvisomant in the ACROSTUDY extension: A real-world experience. Pituitary, 2022, 25, 420-432.	2.9	7
153	Pituitary tumors. Current Treatment Options in Neurology, 2009, 11, 287-296.	1.8	6
154	Pituitary Antibodies in Women with Hashimoto's Thyroiditis: Prevalence in Diagnostic and Prediagnostic Sera. Thyroid, 2012, 22, 509-515.	4.5	6
155	A clinically novel AIP mutation in a patient with a very large, apparently sporadic somatotrope adenoma. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140048.	0.5	6
156	Individuals with isolated congenital GH deficiency due to a GHRH receptor gene mutation appear to cope better with SARS-CoV-2 infection than controls. Endocrine, 2021, 72, 349-355.	2.3	6
157	Pituitary abscess with unusual MRI appearance. Endocrine, 2016, 54, 837-838.	2.3	5
158	Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. Endocrine, 2018, 61, 105-117.	2.3	5
159	Acromegaly in the setting of Tatton-Brown-Rahman Syndrome. Pituitary, 2020, 23, 167-170.	2.9	5
160	Walking and postural balance in adults with severe short stature due to isolated GH deficiency. Endocrine Connections, 2019, 8, 416-424.	1.9	5
161	Growth Hormone-Releasing Hormone Receptor Mutations in Familial Growth Hormone Deficiency. , 2003, 13, 422-427.		4
162	Older individuals heterozygous for a growth hormone-releasing hormone receptor gene mutation are shorter than normal subjects. Journal of Human Genetics, 2015, 60, 335-338.	2.3	4

#	Article	IF	Citations
163	Dopamine agonist withdrawal in hyperprolactinemia: when and how. Endocrine, 2018, 59, 4-6.	2.3	4
164	Immunological and microbiological periodontal profiles in isolated growth hormone deficiency. Journal of Periodontology, 2018, 89, 1351-1361.	3.4	4
165	Deferred Radiotherapy After Debulking of Non-functioning Pituitary Macroadenomas: Clinical Outcomes. Frontiers in Oncology, 2019, 8, 660.	2.8	4
166	Cerebral vasoreactivity, a surrogate marker of cerebrovascular disease, is not impaired in subjects with lifetime, untreated, congenital isolated GH deficiency. Endocrine, 2020, 70, 388-395.	2.3	4
167	Lifetime Growth Hormone (GH) Deficiency: Impact on Growth, Metabolism, Body Composition, and Survival Capacity. , 2012, , 2699-2710.		4
168	Dental arches in inherited severe isolated growth hormone deficiency. Growth Hormone and IGF Research, 2022, 62, 101444.	1.1	4
169	Effects of depot growth hormone replacement on thyroid function and volume in adults with congenital isolated growth hormone deficiency. Journal of Endocrinological Investigation, 2012, 35, 265-8.	3.3	4
170	Growth of teeth and bones in adult subjects with congenital untreated isolated growth hormone deficiency. Growth Hormone and IGF Research, 2022, , 101469.	1.1	4
171	The consequences of growth hormoneâ€releasing hormone receptor haploinsufficiency for bone quality and insulin resistance. Clinical Endocrinology, 2012, 77, 379-384.	2.4	3
172	Vestibular function in severe GH deficiency due to an inactivating mutation in the GH-releasing hormone receptor gene. Endocrine, 2020, 67, 659-664.	2.3	3
173	Phenotypic Analysis and Growth Response to Different Growth Hormone Treatment Schedules in Two Siblings with an Inactivating Mutation in the Growth Hormone-Releasing Hormone Receptor Gene. Journal of Pediatric Endocrinology and Metabolism, 2004, 17, 793-800.	0.9	2
174	Synchronous GH- and prolactin-secreting pituitary adenomas. Endocrinology, Diabetes and Metabolism Case Reports, 2014, 2014, 140052.	0.5	2
175	Bladder pheochromocytoma. Endocrine, 2015, 48, 349-350.	2.3	2
176	Perioperative Glucocorticoid Therapy in Adrenal Insufficiency: What Is the Correct Dose?. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e2078-e2079.	3.6	2
177	Speed of response to dopaminergic agents in prolactinomas. Endocrine, 2022, 75, 883-888.	2.3	2
178	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. Frontiers in Endocrinology, 2022, 13, 840971.	3.5	2
179	A Lifelong Smoker with Hypopituitarism: Rethinking the Hypothesis of a Tumor in the Hypophysis. Case Reports in Medicine, 2012, 2012, 1-4.	0.7	1
180	Lingual thyroid. Endocrine, 2014, 46, 355-356.	2.3	1

#	Article	IF	Citations
181	Posterior pituitary abnormalities caused by pituitary tumors. Current Opinion in Endocrine and Metabolic Research, 2018, 1, 25-28.	1.4	1
182	Caveat regarding CMS Merit-based Incentive Payment Systems incidental adrenal nodule measure. Abdominal Radiology, 2019, 44, 1152-1154.	2.1	1
183	Reduced fibroblast growth factor 21 and Î²-Klotho secretion in untreated congenital isolated GH deficiency. Endocrine, 2021, 73, 160-165.	2.3	1
184	Clinical management of growth hormone therapy in adults. Managed Care, 2009, 18, 10-6.	0.3	1
185	The biochemical diagnosis of acromegaly: revising the role of measurement of IGF-I and GH after glucose load in 5 questions. Expert Review of Endocrinology and Metabolism, 2022, , 1-20.	2.4	1
186	Hypothalamic/pituitary function and dysfunction. , 2002, , 853-870.		0
187	Neuroendocrine Growth Disorders â€“ Dwarfism, Gigantism. , 2012, , 707-721.		0
188	Medical Management of Hormone-Secreting Pituitary Tumors. , 2012, , 203-214.		0
189	Letter to the Editor: Comment on â€œEffect of Growth Hormone Treatment on Fractures and Quality of Life in Postmenopausal Osteoporosis: A 10-Year Follow-Up Studyâ€•by Kratz E., et al. Journal of Clinical Endocrinology and Metabolism, 2015, 100, L107-L107.	3.6	0
190	Posttreatment Management of Cushingâ€™s Disease. , 2017, , 135-167.		0
191	Response to Letter to the Editor From Lukas Andereggen: â€œPitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Reviewâ€• Journal of Clinical Endocrinology and Metabolism, 2021, 106, e3291-e3292.	3.6	0
192	The Incidence of Adrenal Insufficiency in Myeloma Patients Receiving Pulse-Dose Dexamethasone. Blood, 2016, 128, 5640-5640.	1.4	0
193	The Perioperative and Postoperative Care for Pituitary Patients. , 2017, , 59-69.		0
194	Cytopathological Analysis in the Diagnosis of Corticotroph Adenomas: Technical Note. Journal of Neurological Surgery, Part B: Skull Base, 2019, 80, .	0.8	0
195	MON-419 Sellar Plasmacytoma: A Commonly Misdiagnosed Sellar Mass. Journal of the Endocrine Society, 2019, 3, .	0.2	0
196	MON-437 Enteroendocrine Connections in Congenital Isolated GH Deficiency Due to GHRH Receptor Gene Mutation. Journal of the Endocrine Society, 2019, 3, .	0.2	0
197	SUN-LB079 Acrostudy - Safety And Treatment Outcomes In 2221 Patients With Acromegaly Treated With Pegvisomant: Real World Experience. Journal of the Endocrine Society, 2019, 3, .	0.2	0
198	MON-276 Post-Surgical Metabolic Outcomes in Adult-Onset Craniopharyngioma: A Single Pituitary Center Experience. Journal of the Endocrine Society, 2020, 4, .	0.2	0

#	Article	IF	Citations
199	SUN-117 Growth Hormone-Releasing Hormone (GHRH) Deficiency Promotes Inflammation Associated Carcinogenesis. Journal of the Endocrine Society, 2020, 4, .	0.2	0
200	Art and science: impact of semioccluded vocal tract exercises and choral singing on quality of life in subjects with congenital GH deficiency. Archives of Endocrinology and Metabolism, 2022, , .	0.6	0